Drugs / Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05616754 | Nov 2022 → Jul 2023 | COVID-19 | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05616754 ↗ |
| Modality | Vaccine | “The improved vaccine was developed against the Delta and Omicron COVID-19 variants.” NCT05616754 ↗ |